Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
DURHAM, N.C., July 31, 2017 -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients, today announced that it will host a live conference call and audio webcast on Monday, August 7, 2017 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2017, and to provide a business overview.
To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 54730100. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage compounds. In addition, Chimerix has in early-stage development a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT: Investor Relations: [email protected] or Will O’Connor Stern Investor Relations [email protected] 212-362-1200 Media: Becky Vonsiatsky W2O Group [email protected] 413-478-2003
